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Abstract: The already enormous burden caused by Mycobacterium tuberculosis and Human Immunod-
eficiency Virus type 1 (HIV-1) alone is aggravated by co-infection. Despite obvious differences in
the rate of evolution comparing these two human pathogens, genetic diversity plays an important
role in the success of both. The extreme evolutionary dynamics of HIV-1 is in the basis of a robust
capacity to evade immune responses, to generate drug-resistance and to diversify the population-
level reservoir of M group viral subtypes. Compared to HIV-1 and other retroviruses, M. tuberculosis
generates minute levels of genetic diversity within the host. However, emerging whole-genome
sequencing data show that the M. tuberculosis complex contains at least nine human-adapted phylo-
genetic lineages. This level of genetic diversity results in differences in M. tuberculosis interactions
with the host immune system, virulence and drug resistance propensity. In co-infected individuals,
HIV-1 and M. tuberculosis are likely to co-colonize host cells. However, the evolutionary impact of
the interaction between the host, the slowly evolving M. tuberculosis bacteria and the HIV-1 viral
“mutant cloud” is poorly understood. These evolutionary dynamics, at the cellular niche of mono-
cytes/macrophages, are also discussed and proposed as a relevant future research topic in the context
of single-cell sequencing.
Keywords: HIV-1; Mycobacterium tuberculosis; evolutionary genetics; lineage; subtype; genetic diver-
sity; tuberculosis; AIDS
1. Introduction
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis infection, is one of
the top ten leading causes of death worldwide [1,2]. Among the estimated 1.4 million TB
deaths in 2019, 208,000 individuals were co-infected with the Human Immunodeficiency
Virus (HIV), representing approximately 30% of the Acquired Immunodeficiency Syndrome
(AIDS) related deaths (from a total of 690,000 [3]). Indeed, TB represents the leading cause
of morbidity and mortality among AIDS patients [1,3,4]. Several efforts have been made to
prevent transmission and treat the viral infection, relying on antiretroviral therapy (ART),
which contributed to the avoidance of 12.1 million deaths due to AIDS related illnesses
between the years 2010 and 2019 [3]. Regarding M. tuberculosis/HIV co-infection, the
combined effect of ART and TB treatment prevented 11 million deaths between 2000 and
2019 [1].
According to the World Health Organization (WHO) in 2019, the risk of developing
TB was 15 to 21 times higher in people infected with HIV. Within the same host, HIV and
M. tuberculosis present a synergetic relationship, leading to a faster deterioration of the
immune system and, consequently, to reduced life expectancy [5]. In fact, studies have
shown that low CD4+ T cell counts in HIV-infected patients relate with a higher probability
of developing active TB [4,6–8], while individuals undergoing ART therapy are less prone
to develop TB [4].
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One of the biggest challenges concerning TB treatment is the existence of drug-resistant
M. tuberculosis strains. In 2019, approximately 500,000 cases of resistance to rifampicin,
the most effective first-line drug, were reported, from which 78% presented multidrug-
resistance (MDR) [1]. Interestingly, transmission of drug-resistant strains is considered
the main contributor to this phenomenon, rather than genetic alterations of the bacterial
genome arising de novo within infected individuals [9].
Contrasting with several other human pathogens, M. tuberculosis generates smaller
genetic diversity levels within the host and at the transmission chain levels [10–12]. Still,
two M. tuberculosis strains can differ in thousands of single nucleotide polymorphisms
(SPNs) and associate with different clinically relevant phenotypes [11,13–17]. In addition,
analysis of M. tuberculosis genomes revealed a biased geographic distribution for the
phylogenetic lineages of the pathogen, supporting a possible adaptation to specific host
populations [13,18–23].
On the other hand, HIV-1 presents extremely high genetic variability at the intrahost
and population levels [24,25]. HIV-1 subtypes and recombinant forms have a dissimilar
global distribution [26,27], and present distinct cell tropism, viral fitness and plasma viral
loads, which may play a role on the infection dynamics, disease progression and in the
response to ART [28,29]. Moreover, HIV-1 genetic diversity is behind the emergence of
drug-resistant viruses and underlies the biggest challenges to find an effective treatment or
cure to HIV-1 infection [30].
In this review, we describe the genetic diversity and evolution of M. tuberculosis and
HIV-1, with particular emphasis on its biomedical implication and impact in host–pathogen
interactions. We then propose the evolutionary dynamics of the interaction between the
host, M. tuberculosis and HIV-1, at the cellular niche of monocytes/macrophages, as a future
research challenge to the field.
2. Genetic Diversity of M. tuberculosis
2.1. M. tuberculosis Lineages: Origin and Host-Pathogen Associations
The Mycobacterium tuberculosis complex (MTBC) is composed of obligate pathogens
with no known environmental reservoir [20,21,31]. Mycobacterium spp. from the MTBC
share high levels of DNA sequence identity, which leads to controversial taxonomy and
nomenclature [32,33]. Despite this, members of the MTBC differ widely in host range
and geographic distribution [14,18–20,31,32]. There is a clear interspecies difference in the
ability to cause active disease, with animal-adapted bacteria such as M. bovis or M. orygis
being isolated occasionally in humans and associated with extra-pulmonary forms of the
disease [20,31,34]. On the other hand, although the human pathogen M. tuberculosis has
been occasionally isolated in other animals [35], associated pathology in the lungs and
lymph nodes of cattle was found to be very low comparatively to M. bovis [36].
Human-adapted MTBC bacteria are divided into at least nine distinct lineages, as de-
termined by whole-genome phylogenetic analysis using clinical isolates from several world
regions [13,37,38]. These lineages are thought to have originated several millennia ago in
the Neolithic period [39], with their phylogeographic pattern subsequently defined by so-
ciodemographic events [13,22,40,41] and biological factors [10,15,32,42–44]. The “ancient”
lineages 1, 5, 6 and the newly proposed lineage 9 (based on five genomes isolated from
East African countries [38]) were considered the first to split from the common ancestor,
while the “modern” lineages (lineages 2, 3 and 4) diverged later. Lineage 1 strains are more
abundant in East Africa, Southeast Asia, South Asia and Oceania; lineage 2 in Eastern Asia
(e.g., China); lineage 3 in East Africa, Southwest Asia, Central and South Asia; lineage 4 in
Europe, Africa and America; lineages 5 and 6 are typically restricted to West Africa and
lineage 7 was only isolated in Northern Ethiopia (Figure 1 and [13,45,46]). Additionally,
two M. tuberculosis genomes from Rwanda and Uganda highlighted the existence of a
sister clade to the MTBC (i.e., with an immediate common ancestor), which was named
Lineage 8 [37]. The geographic distribution of these phylogenetic lineages across the
globe is not likely to be a mere consequence of founder effect. Instead, it seems to be
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partially driven by the interaction with specific human populations [13,20,21]. Strikingly,
the phylogeographic profile of M. tuberculosis is maintained even in highly urbanized
settings, as demonstrated for San Francisco (USA). In this metropolis, the active TB cases in
immigrant communities were predominantly caused by strains belonging to lineages that
were characteristically abundant in the patient’s country of origin, rather than the highly
prevalent lineage 4 strains [18,47]. On a similar note, the predominant sublineages in bor-
dering areas of Southeast Asia were found to be different, contrasting with the high level
of interregional flows of people [48]. This fact suggests that some level of host–pathogen
co-adaptation exists and is important to the development of active TB. M. tuberculosis
lineages are also substantially different in terms of human host population range, which
might reflect on the relative success to cause active disease. Indeed, lineages 2 and 4 cover
considerably more territory than the remaining lineages (Figure 1). Moreover, lineage 4 was
isolated in patients from all inhabited continents. Nevertheless, certain sublineages of lin-
eage 4 are more geographically restricted than others [23]. In addition, robust phylogenetic
dating revealed the existence of these “specialist” sublineages over many centuries [46],
demonstrating that there was enough time for a more global spread in light of globalization
and airborne transmission. Interestingly, “specialist” sublineages presented lower levels of
sequence diversity in experimentally validated T cell epitopes [23], indicating a possible
role for human adaptive immune system in the definition of host-pathogen combinations
that can more likely result in active TB after infection [23].
Figure 1. Global distribution of the genetic diversity of Mycobacterium tuberculosis and Human Immunodeficiency Virus
typ1 1 (HIV-1). (a) Frequencies of M. tuberculosis lineages (outer ring/circle) and HIV-1 subtypes (inner ring/circle)
across 10 geographic regions. Pie chart size is related with both diseases’ prevalence in each region [1,3]. Geographic
regions are according to Los Alamos HIV database (http://www.hiv.lanl.gov/) [25]. M. tuberculosis spoligotype clades
(n = 64,555 sequences) were extracted from the SITVIT2 database [49] and converted to Mycobacterium tuberculosis complex
(MTBC) lineages 1–6 [45,50,51]. HIV-1 data (n = 815,431 sequences) were obtained from Los Alamos HIV database [25].
(b) Global frequency of M. tuberculosis lineages and HIV-1 subtypes. The estimated number of people living with TB or
HIV-1 was obtained from the World Health Organization (WHO) [1] or from the Joint United Nations Programme on
HIV/AIDS (UNAIDS) [3].
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2.2. Biomedical Implication of M. tuberculosis Genetic Diversity
The population structure of M. tuberculosis was shown to influence several biomedi-
cally relevant aspects, such as transmissibility, disease severity, drug resistance and immune
response (as extensively covered in previous reviews [10,15]). Here, we describe evidence
of the interaction of M. tuberculosis with distinct human genetic backgrounds and HIV-1.
Transmissibility of a pathogen might ultimately dictate its prevalence among host
populations. The transmission potential of “modern” MTBC lineage strains has a tendency
to be higher than in their “ancient” partners [15,52]. Increases in relative prevalence have
been consistently reported in several world regions for Lineage 2 [15,53–55]. In agreement,
three quarters of the transmission clusters in Ho Chi Minh City (Vietnam) involved recently
introduced lineage 2 strains [54]. Importantly, lineage 2 strains progressed to active disease
in younger people and in shorter periods of time, while the endemic lineage 1 led to
increased chance of reactivation from latent TB and in older people [54]. Another study
demonstrated the ability of the Beijing sublineage of lineage 2 (L2-Beijing) to spread to
Africa, following a series of multiple and timely independent events [55]. This suggests
that the introduction of L2-Beijing was not solely due to its increased mutation rate,
previously found to augment drug resistance acquisition in vitro [56]. Overall, both host
and bacterial factors might be involved in the colonization of different ecological niches
by M. tuberculosis lineages. One interesting approach is to dissect this issue in light of
the large disease spectrum of TB. TB manifestations can range from latency or subclinical
disease [57] to increased severity [17]. To bring clarity to these topics, some authors are
addressing the host and pathogen simultaneously. For instance, a significant association
was reported between a nonsynonymous substitution (G254K) on the Arachidonate 5-
Lipoxygenase (ALOX5) gene and increased predisposition to develop TB due to lineage 6.
Accordingly, the variant G254K of ALOX5 is highly frequent in Africa when compared to
other world regions [58], indicating that lineage 6 strains (abundant in West Africa) might
have a selective advantage in hosts harboring the referred polymorphism. In a genome-
wide association study (GWAS) with nearly 700 M. tuberculosis clinical isolates, a SNP near
the leukocyte surface antigen CD53 gene was significantly associated with older age onset
TB cases caused by lineages other than lineage 2 [59]. Interestingly, results are in agreement
with the different transmission dynamics by lineage described for Ho Chi Minh City
(Vietnam) [54]. On the other hand, recent work [17] could not find a single SNP explaining
all the association between severe TB and M. tuberculosis clinical isolates inducing low levels
of IL-1β secretion. Instead, several candidate mutations were found, with possible impacts
at the protein level (ESX-1 secretion system) and transcription regulation (sigma factor
sigA). These data show a complex interaction between the bacterium and the immune
system of its host.
CD4+ T cells are crucial immune components to control M. tuberculosis [8]. This is
particularly evident when viewed in the context of HIV-1 co-infection. A molecular epi-
demiology study performed by Lukas Fenner and colleagues [7] showed a significantly
higher percentage of active TB infections due to allopatric M. tuberculosis strains (i.e., be-
longing to lineages not usually associated with the patient’s country of origin) in cases of
HIV-1 co-infection. The statistical association was stronger in patients with lower CD4+
T cell counts and remained significant after adjusting for sex, age, contact with foreign
populations and immune comorbidities. Thus, these results highlight the importance of
studying the immune synapse between bacterial peptides and different human leukocyte
antigen (HLA) class II proteins. However, a large majority of the experimentally validated
T cell epitopes were described to be hyperconserved across the MTBC [60,61]. Nonetheless,
amino acid mutations in predicted CD4+ T cell epitopes were identified in a comprehen-
sive immunoinformatic screening aiming at highly diverse genes. Furthermore, amino
acid variants in 10 out of 14 experimentally tested epitopes led to differential immune
responses, as measured by IFN-y secretion in the blood of 82 individuals from the Gambia,
latently infected with M. tuberculosis [61]. Other elaborated approaches have been also
uncovering relevant CD4+ T cell epitopes, including some that are highly prevalent in
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certain MTBC lineages [62–64]. Another important feature of the immune response in TB
is the balance between pathogen clearance and immunopathology [8,10]. In this context,
a recent study reported the death of a patient with Merkel cell carcinoma after the use of
anti-T cell inhibitory receptor PD-1 as an immunotherapeutic strategy, possibly caused by
an exacerbated immune response [65]. Overall, immune findings highlight the need for an
integrative approach to diagnose and treat TB, taking into account important comorbidities
such as the ones caused by HIV-1.
3. Genetic Diversity of HIV-1
3.1. HIV-1 Groups and Subtypes
The world became aware of HIV-1 in the 1980s. However, by that time there was
already a large dissemination of the virus. Although it was first described in the American
continent, it became evident by subsequent studies that it already had a high prevalence in
the central and eastern African populations [66,67]. The genetic proximity between HIV-1
and simian immunodeficiency virus (SIV), observed in African nonhuman primates (NHPs),
was a fundamental piece of evidence to understand the origin of this pandemic [68,69].
Today it is widely accepted that retroviruses can be transmitted to humans from the blood
or tissues of NHPs. This exposure may be a consequence of pet handling or hunting for
bushmeat [70,71]. The division of HIV-1 in several groups is a direct consequence of the
genetic distance observed among them, caused by independent cross-species transmis-
sion events [72]. Groups M and O were most likely the first circulating among human
populations [73]. However, the closest SIV to group M is found in chimpanzees (SIVcpz,
Pan troglodytes troglodytes) [74], while the group O counterpart was identified in gorillas
(SIVgor, Gorilla gorilla) [75]. Group N is also closely related with SIVcpz [74]. In 2009 a
new cross-species transmission event was reported. A virus closely related with SIVgor,
differing from group O, was observed in a human host giving rise to the group P [76].
Later, more cases of this novel group were reported [77]. Although four different HIV-1
groups exist (M, N, O and P), only M caused a pandemic. As previously mentioned, group
P was only observed in sporadic cases [77], N is largely confined to Cameroon [78] and O
can be found mainly in west and south-east African countries [79]. Consequently, the term
“HIV-1” is commonly used when referring to HIV-1 group M, and only when referring to
other groups is the corresponding letter specified. By using molecular clock estimations,
it was possible to date the early spread of HIV-1 group M and O among human populations
to the 1920s [73] in the Congo River basin. Faria et al. [73] estimated the HIV-1 population
growth with a two-phase exponential-logistic model, concluding that between 1920 and
1960 both group M and O had relatively slow exponential growths and were restricted to
the Kinshasa area. However, around 1960, the growth rate of group M more than doubled
while group O remained practically unchanged. The success of group M is most likely
due to the unfortunate coincidence of several viral characteristics and human sociodemo-
graphic factors. The Vpu protein in group M seems to be more efficient regarding immune
system evasion, leading to higher viral replication rates [80]. Historical records support the
massive use of unsterilized injection material in the Kinshasa region, which is thought to
be the cause of a hepatitis outbreak in the early 1950s [81]. Moreover, the sex commerce in
the region saw several alterations in the 1960s—namely, the increased number of clients per
sex worker [81]. These and other factors may have led to the observed superior exponential
growth of HIV-1 group M which resulted in today’s pandemic.
The HIV-1 diversity is not restricted to group differences. Most of the modern-day
cohort characterizations focus on the HIV-1 group M subtype level [82–84]. There are
nine subtypes (A–D, F–H, J, K) some of which include sub-subtypes (A: A1, A2, A3, A4,
A6 and F: F1, F2). However, some literature suggests the possibility of other severely
underreported subtypes [85]. The vast genetic diversity of this pathogen is a consequence
of its capacity to generate high viral loads while maintaining high mutation and replication
rates [86–88]. The ability of the virus to rapidly accumulate changes has a tremendous effect
on its success, allowing it to quickly adapt to a new host environment [72]. The generation
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of mutations in the HIV-1 genome is largely attributed to the viral Reverse transcriptase
(RT), which has no proofreading activity. Retroviruses have two copies of the genomic RNA
per virion. During the process of reverse transcription, portions of both RNA molecules
can be used to generate the resulting DNA molecule. Thereafter, retroviruses have high
recombination rates—among them, HIV-1 has one of the highest [89,90]. Recombination
may occur between two viral RNA copies of the same HIV-1 group M subtype, and after
integration in the host genome, viral particles of the same subtype will be created from the
resulting DNA. However, cases of multiple infections by viruses of different subtypes may
lead to the emergence of recombinant variants [91]. These are generally called HIV-1 group
M recombinant forms. If only sporadic cases of a given form are observed, the nomenclature
Unique Recombinant Form (URF) is used. However, if a transmission chain is originated,
leading to the appearance of a high number of infections by the new recombinant form this
will be denoted as a Circulating Recombinant Form (CRF) [92]. The number of identified
HIV-1 group M CRFs is continuously increasing. At the time of writing, the HIV-1 sequence
database has recorded more than 90 CRFs [93].
The classification of HIV-1 in groups and subtypes is extremely useful in terms of
epidemic surveillance. HIV-1 subtyping tools [94–97] are user friendly and can be used
to quickly infer the HIV-1 subtype from the viral sequence. The subtype information can
be used as a proxy of diversity. For instance, the increase in a rare subtype prevalence
among new infections may be the indication of new patterns of transmission or behavior
in a given population. Moreover, observing a large number of recent infections by the
same subtype may be an indicator of a vast transmission chain that must be identified
and tackled [83,98]. The nomenclature proposal made by Robertson et al. [92] was a core
document to normalize and created a reference classification for HIV-1.
The global distribution of HIV-1 subtypes is uneven (Figure 1). It is estimated that
subtype C accounts for almost 50% of the HIV-1 infections worldwide, being more prevalent
in the African continent. The most well studied subtype is B, a result of its high prevalence
in the Americas, Europe and Australia [82,99]. Since it is the geographic origin of HIV-1,
the countries in the central east region of Africa have the highest subtype diversity.
3.2. HIV-1 Viral “Quasispecies”—HIV-1 Intra Host Diversity
Most HIV-1 hosts were exposed to a single transmission event. Nevertheless, in what
is thought to be a relatively rare occurrence the same host can be exposed to multiple
HIV-1 transmission events [91]. The term dual infection is sometimes applied referring
to multiple infections, which should be done thoughtfully since it assumes only two
events. However, dual infection is a practical term when referring to the “previous” and
the “following” infections. Therefore, dual infection can be divided into co-infection or
superinfection. Co-infection refers to two infection events occurring within a brief period.
On the other hand, a superinfection refers to a subsequent infection after the establishment
of a complete immune response to the first event [91,100]. The different infection events
can harbor similar or very distinct HIV-1 genomes. The presence in the same host of viruses
from different HIV-1 group M subtypes raises the potential of recombination among them
generating recombinant forms [101]. Even recombination among viruses from the same
subtype can aid the virus to successfully adapt to the host. Different viral particles, in the
same host, can harbor beneficial genetic characteristics, which when combined (due to
recombination) can lead to the emergence of a virus with greater fitness. The process of
selecting successful viral variants occurs in a trial and error manner and is only possible due
to the large viral load generated by HIV-1 infection [101,102]. This within host variability is
sometimes referred to as “quasispecies”. This term attributed to Eigen [103,104] describes
the pool of different, yet similar, genomes accumulating genetic variations, competing,
and being selected within host [105]. This “cloud” of viral genomes allows the viral
population to escape, or at least partially escape, host immune and antiretroviral treatment
(ART) pressures.
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3.3. Biomedical Implication of HIV-1 Genetic Diversity
HIV-1 infections by groups N, O and P have clinical manifestations distinguishable
from the pandemic group M. However, their occurrence is rather rare [72,74,75,77–79].
Several studies focused on enlightening the impact of the M group subtype diversity in
clinical correlates. It was demonstrated that subtype A leads to a slower decline of CD4+
T cell counts and consequently slower disease progression when compared, in several
cohorts, to subtypes C and D [106–108]. This seems to be independent of viral load [108,109].
Additional comparisons between these three subtypes suggest a preference for in utero
transmission of subtype C [110,111]. The genetic differences observed among subtypes
can sometimes correspond to sites targeted by ART. Of note, ART was largely developed
focusing on subtype B, due to its geographic distribution [112]. Therefore, differences in
the prevalence of certain polymorphisms can lead to a differential response to ART. This
was observed for all the viral proteins targeted by treatment so far [113–115]. Although
subtype differences may affect treatment susceptibility, their impact is limited, and ART is
expected to be efficient across subtypes [116]. CD8+ T cells have a crucial importance in
antiviral immunity [117], and consequently the viral regions encoding epitopes recognized
by these cells are known to accumulate escape mutations [118,119]. Similarly to what
was previously described for the ART, the subtype diversity can impact the immune
response capacity [120]. As previously reviewed in more detail by Carlson et al., having
a higher (several mutations) or lower (few mutations) barrier to the appearance of the
escape variants when exposed to a given set of immune pressures can have an impact on
the infection progression of the different HIV-1 subtypes [119,121].
Viral cellular reservoirs represent one of the biggest challenges towards the cure of
HIV-1 infection, as the virus is able to maintain residual replication levels even during
ART treatment, chronically compromising the host immune system [122–124]. HIV-1
genetic diversity also seems to play a role in viral preferential tropism. Differences in
cellular reservoirs preference in the lymph nodes have been observed by Bhoopat and
colleagues [125,126] between HIV-1 subtypes B and CRF01_AE (previously known as
E subtype). A more recent study also demonstrated that subtype B established larger
reservoirs when compared with the subtypes CRF01_AE and G, with larger reservoirs
related to worse prognosis [127].
Overall, the genetic diversity of HIV-1, represented in the form of groups, subtypes,
and recombinants, is the largest obstacle for the creation of an effective and comprehensive
strategy to prevent or cure AIDS [119,128,129].
4. Conclusions and Future Perspectives
Infectious diseases were traditionally investigated in an isolated or pairwise fashion
considering a single pathogen and the host. However, humans are in constant inter-
action with the microbiome and are often infected by multiple pathogens. Moreover,
host–pathogen interactions consist of a complex network of protein–protein interactions
that influences the evolution of the interrelating entities at each given time. In the cases
of M. tuberculosis and HIV-1, both gain reciprocal advantages in co-infecting the human
host. Nevertheless, it remains elusive how and to what extent the evolving community of
viruses and bacteria within an infected host can communally shape genetic diversity and
evolutionary patterns.
Since macrophages are the primary intracellular niche for M. tuberculosis and are also
permissive to HIV-1 infection, it is likely that the two pathogens can modulate/compromise
these cells, facilitating co-infection and contributing to accelerate the progression of
both diseases.
The most important co-receptors for HIV-1 binding and cell entry are CCR5 and
CXCR4. Virions can display affinity for both receptors or increased affinity to either CCR5
or CXCR4. For reasons that are not fully understood and regardless of the infection route,
CCR5-tropic viruses are the most transmitted [130]. Thus, CCR5 receptors are considered
to play a central role in the initial stages of HIV-1 infection. In addition to memory CD4+ T
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cells, CD4 and CCR5 are also expressed in monocytes and macrophages [131]. However,
efficient replication of HIV-1 within infected macrophages is limited by the restriction
factor SAMHD1 [132]. The activity of SAMHD1 is downregulated when macrophages
are in a G1-like state allowing HIV-1 to bypass SAMHD1 restriction [133]. Interestingly,
it has been shown that M. tuberculosis infection inhibits the macrophage G1/S transition
arresting the macrophages in the G0-G1 phase [134]. Thus, it is tempting to speculate that
M. tuberculosis-infected macrophages become more permissive to allow HIV-1 replication.
Possible consequences of higher HIV-1 viral loads in the infected macrophages are an
increase in the intrahost viral genetic diversity and a more rapid conversion from an initial
population of CCR5-tropic viruses to a mixed population of CCR5- and CXCR4-tropic
viruseses, expanding the possibilities for the virus to target other host cells.
On the other hand, the increased severity of TB in HIV-1/M. tuberculosis co-infected
individuals was shown to be dependent on CD4+ T cell counts [135]. Since CD4+ T cells
are the primary target cells of HIV-1 and are also central for the control of M. tuberculosis
infection [136,137], it is very likely that the aggravation of TB due to HIV-1 infection is
caused by a decrease in the host protective responses against M. tuberculosis. Furthermore,
the large increase in the risk of developing active TB in HIV-infected individuals is present
even at early stages of infection with normal CD4+ T cells counts [138,139]. This suggests
that other factors might be involved but it is also relevant to consider that during the
progressive depletion of CD4+ T cells, less frequent clones might become absent even at
levels of total CD4+ T cells that are considered normal. Fenner and colleagues [7] showed
that in HIV-1/M. tuberculosis co-infected individuals, there is a significant increase in
cases of active TB due to M. tuberculosis strains belonging to lineages that do not usually
occur in that particular geographic region [7]. M. tuberculosis lineages show high levels
of conservation in T cell epitopes. Nonetheless, outlier epitopes to the general rule of
hyperconservation have been described [61,140]. It was shown that because of this there is a
higher degree of host-pathogen variability in T cell responses than previously expected [61].
Thus, it is conceivable that during the HIV-1 inflicted depletion of CD4+ T cells, the capacity
of the host to control specific lineages of M. tuberculosis and prevent the transition from
latent to active TB is compromised.
Overall, the interaction between HIV-1, M. tuberculosis and their obligate human hosts
is determined by a complex network of host, pathogen and environmental factors. We
propose that in co-infected hosts, HIV-1 and M. tuberculosis mutually influence their genetic
evolutionary dynamics. This is likely to occur in potentially overlapping intracellular
niches, such as monocytes/macrophages, and via CD4+ T cells. Thus, we highlight single-
cell RNA sequencing (scRNA-seq), which has been highlighted as a valuable tool to study
both viral and bacterial interactions with the host [141–143], as a technique to be used
in future studies since it could provide crucial insights into the synergy of HIV-1 and M.
tuberculosis within the same cellular niches.
Future integrated strategies to further understand this crosstalk between HIV-1 and M.
tuberculosis can help in disease control and in the clinical and epidemiological stratification
of high-risk populations.
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